Limited numbers of dual PI3K/mTOR inhibitors have progressed to clinical trials in ovarian cancer, despite numerous pre-clinical studies showing positive anti-tumor activity and outcomes. The gene discussed is PIK3CB; the disease is ovarian carcinoma.